8-K Announcements
6Material company update
May 19, 2026·SEC
Material company update
May 14, 2026·SEC
Material company update
May 4, 2026·SEC
Onconetix, Inc.(ONCO)Earnings, Financials & Key Ratios
ONCO•NASDAQ
Price updated Jun 19, 2026
AboutOnconetix, Inc., a biotechnology and pharmaceutical company, focuses on developing and commercializing transformational therapies to address health challenges worldwide. The company owns Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia. It is also developing a streptococcus pneumoniae vaccine candidate, which is designed to prevent infectious middle ear infections in children, and prevention of pneumonia in the elderly; and universal flu vaccine that provide protection from all virulent strains in addition to licensing a novel norovirus S&P nanoparticle versatile virus-like particle vaccine platform from Cincinnati Children's to develop vaccines for multiple infectious diseases, including Marburg and monkeypox, and others. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.Show more
- Revenue$815K-67.7%
- EBITDA-$6M+88.6%
- Net Income-$14M+76.1%
- EPS (Diluted)-4.73+99.1%
- Gross Margin77.62%+85.7%
- EBITDA Margin-776.3%+64.9%
- Operating Margin-778.16%+65.2%
- Net Margin-1720.98%+26.0%
- ROE-110.6%+89.6%
ONCO Key Insights
Onconetix, Inc. (ONCO) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Trading at only 0.2x book value
✗Weaknesses
- ✗Profits declining 54.4% over 5 years
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 0 (bottom 0%)
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when ONCO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ONCO Price & Volume
Onconetix, Inc. (ONCO) stock price & volume — 10-year historical chart
Loading chart...
ONCO Growth Metrics
Onconetix, Inc. (ONCO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-61.81%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM82.71%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM98.31%
Return on Capital
10 Years-76.62%
5 Years-98.3%
3 Years-89.33%
Last Year-49.41%
ONCO Recent Earnings
Onconetix, Inc. (ONCO) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 2/12 qtrs (67%)
Q2 2026Latest
May 13, 2026Metric
Actual
Est
EPS
$6.71
—
Rev
$21,457
—
Q2 2026
Mar 12, 2026Metric
Actual
Est
EPS
$12.58
—
Rev
$303,596
—
Q4 2025
Nov 13, 2025Metric
Actual
Est
EPS
$6.25
—
Rev
$303,651
—
Q3 2025
Aug 14, 2025Metric
Actual
Est
EPS
$4.05
—
Rev
$106,494
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $6.71 | $21,457 |
| Q2 2026 | Mar 12, 2026 | $12.58 | $303,596 |
| Q4 2025 | Nov 13, 2025 | $6.25 | $303,651 |
| Q3 2025 | Aug 14, 2025 | $4.05 | $106,494 |
Based on last 12 quarters of dataView full earnings history →
ONCO Peer Comparison
Onconetix, Inc. (ONCO) competitors in Vaccines and Infectious Disease — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 CRVS | 1B | 11.91 | -22.47 | -38.92% | 0.02 | |||
 AGEN | 124.93M | 3.00 | -882.35 | 10.37% | 52.16% | |||
 IMVT | 7.26B | 35.34 | -12.76 | -68.16% | 0.00 | |||
 NUVL | 9.08B | 123.43 | -21.10 | -42.78% | ||||
 PRAX | 8.15B | 282.31 | -20.94 | -100% | -43.02% | 0.00 | ||
 JANX | 867.2M | 14.22 | -7.77 | -5.55% | -5.3% | -11.85% | 0.02 | |
 ARCC | 12.95B | 18.03 | 9.69 | 32.87% | 43.69% | 8.11% | 1.12 | |
 ORIC | 878.86M | 8.49 | -5.78 | -35.33% | 0.03 |
Compare ONCO vs Peers
Onconetix, Inc. (ONCO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ONCO Income Statement
Onconetix, Inc. (ONCO) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 58.47K | 2.52M | 815.37K | 735.2K |
Revenue Growth % | - | - | - | - | - | 4217.31% | -67.7% | -61.81% |
Cost of Goods Sold | 573 | 3.06K | 4.89K | 6.75K | 1.19M | 1.47M | 182.46K | 149.77K |
COGS % of Revenue | - | - | - | - | 2027.93% | 58.2% | 22.38% | - |
Gross Profit | -573▲ 0% | -3.06K▼ 433.3% | -4.89K▼ 60.0% | -6.75K▼ 38.1% | -1.13M▼ 16593.8% | 1.06M▲ 193.6% | 632.91K▼ 40.0% | 585.43K▲ 0% |
Gross Margin % | - | - | - | - | -1927.93% | 41.8% | 77.62% | 79.63% |
Gross Profit Growth % | - | -433.33% | -60.01% | -38.08% | -16593.79% | 193.61% | -40.01% | - |
Operating Expenses | 879.66K | 1.62M | 3.42M | 13.48M | 34.91M | 57.54M | 6.98M | 7.37M |
OpEx % of Revenue | - | - | - | - | 59706.54% | 2279.76% | 855.78% | - |
Selling, General & Admin | 819.49K | 1.1M | 2.09M | 9.35M | 14.77M | 11.23M | 7.04M | 7.41M |
SG&A % of Revenue | - | - | - | - | 25264.14% | 444.99% | 863.89% | - |
Research & Development | 60.17K | 524.91K | 1.33M | 4.13M | 1.95M | 154.36K | -66.13K | -39.77K |
R&D % of Revenue | - | - | - | - | 3334.31% | 6.12% | -8.11% | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 18.19M | 46.16M | 0 | 0 |
Operating Income | -880.23K▲ 0% | -1.62M▼ 84.3% | -3.42M▼ 110.7% | -13.48M▼ 294.5% | -36.03M▼ 167.3% | -56.49M▼ 56.8% | -6.34M▲ 88.8% | -6.78M▲ 0% |
Operating Margin % | - | - | - | - | -61634.47% | -2237.96% | -778.16% | -922.72% |
Operating Income Growth % | - | -84.28% | -110.68% | -294.5% | -167.29% | -56.76% | 88.77% | - |
EBITDA | -879.66K | -1.62M | -3.41M | -13.47M | -35.99M | -55.76M | -6.33M | -6.77M |
EBITDA Margin % | - | - | - | - | -61559.32% | -2208.99% | -776.3% | -920.57% |
EBITDA Growth % | - | -84.05% | -110.77% | -294.86% | -167.1% | -54.92% | 88.65% | 85.45% |
D&A (Non-Cash Add-back) | 573 | 3.06K | 4.89K | 6.75K | 43.94K | 731.35K | 15.17K | 15.82K |
EBIT | -821.91K | -1.6M | -3.42M | -13.42M | -36.75M | -58.33M | -13.28M | -9.17M |
Net Interest Income | 58.32K | 22.6K | 0 | 0 | -671.63K | -1.41M | -751K | -529.66K |
Interest Income | 58.32K | 22.6K | 0 | 0 | 0 | 18 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 671.63K | 1.41M | 751K | 529.66K |
Other Income/Expense | 58.32K | 22.6K | 0 | 61.41K | -1.39M | -3.25M | -7.69M | -2.92M |
Pretax Income | -821.91K▲ 0% | -1.6M▼ 94.6% | -3.42M▼ 113.7% | -13.42M▼ 292.7% | -37.42M▼ 178.9% | -59.74M▼ 59.6% | -14.03M▲ 76.5% | -9.7M▲ 0% |
Pretax Margin % | - | - | - | - | -64008.02% | -2366.62% | -1720.91% | -1319.48% |
Income Tax | 0 | 0 | 0 | 0 | -12.59K | -1.05M | 525 | 525 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0.03% | 1.75% | -0% | -0.01% |
Net Income | -821.91K▲ 0% | -1.6M▼ 94.6% | -3.42M▼ 113.7% | -13.42M▼ 292.7% | -37.41M▼ 178.8% | -58.69M▼ 56.9% | -14.03M▲ 76.1% | -9.7M▲ 0% |
Net Margin % | - | - | - | - | -63986.48% | -2325.21% | -1720.98% | -1319.55% |
Net Income Growth % | - | -94.6% | -113.65% | -292.7% | -178.76% | -56.89% | 76.09% | 82.71% |
Net Income (Continuing) | -821.91K | -1.6M | -3.42M | -13.42M | -37.41M | -58.69M | -14.03M | -9.7M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 7.01M | 0 | 0 | 0 |
EPS (Diluted) | -0.02▲ 0% | -0.04▼ 87.8% | -0.09▼ 121.5% | -0.31▼ 251.5% | -25.03▼ 7937.4% | -520.93▼ 1981.3% | -4.73▲ 99.1% | -15.44▲ 0% |
EPS Growth % | - | -88.17% | -121.43% | -251.61% | -7936.7% | -1981.34% | 99.09% | 98.31% |
EPS (Basic) | -0.02 | -0.04 | -0.09 | -0.31 | -25.03 | -520.93 | -4.73 | - |
Diluted Shares Outstanding | 11.37K | 11.37K | 11.37K | 12.63K | 17.61K | 113.05K | 3.28M | 628.53K |
Basic Shares Outstanding | 11.37K | 11.37K | 11.37K | 12.63K | 17.61K | 113.05K | 3.28M | 628.53K |
Dividend Payout Ratio | - | - | - | - | - | - | - | - |
ONCO Balance Sheet
Onconetix, Inc. (ONCO) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Total Current Assets | 6.06M | 4.6M | 3.07M | 26.26M | 5.84M | 950.27K | 6.07M | 4.33M |
Cash & Short-Term Investments | 6.05M | 4.31M | 1.93M | 25.75M | 4.55M | 646.5K | 5.22M | 3.72M |
Cash Only | 6.05M | 4.31M | 1.93M | 25.75M | 4.55M | 646.5K | 5.22M | 3.72M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 8.33K | 44.8K | 152.52K | 35.85K | 149.73K | 96.31K | 296.87K | 43.73K |
Days Sales Outstanding | - | - | - | - | 934.78 | 13.93 | 132.89 | 55.18 |
Inventory | 0 | 0 | 0 | 0 | 364.05K | 64.08K | 149.96K | 137.64K |
Days Inventory Outstanding | - | - | - | - | 112.07 | 15.92 | 299.99 | 360.82 |
Other Current Assets | 0 | 0 | 757.65K | 0 | 0 | 0 | 92K | 56.34K |
Total Non-Current Assets | 21.93K | 215.6K | 11.5K | 52.71K | 81.68M | 27.23M | 18.86M | 10.5M |
Property, Plant & Equipment | 6.93K | 15.67K | 11.5K | 14.09K | 209.2K | 182.32K | 85.86K | 74.26K |
Fixed Asset Turnover | - | - | - | - | 0.28x | 13.84x | 9.50x | 10.82x |
Goodwill | 0 | 0 | 0 | 0 | 55.68M | 27.05M | 18.55M | 10.2M |
Intangible Assets | 0 | 0 | 0 | 0 | 25.41M | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 250.31K | 0 | 0 |
Other Non-Current Assets | 15K | 199.93K | 0 | 38.62K | 383.54K | -250.31K | 225K | 225K |
Total Assets | 6.08M▲ 0% | 4.81M▼ 20.9% | 3.08M▼ 35.9% | 26.31M▲ 752.9% | 87.52M▲ 232.6% | 28.18M▼ 67.8% | 24.93M▼ 11.5% | 14.83M▲ 0% |
Asset Turnover | - | - | - | - | 0.00x | 0.09x | 0.03x | 0.04x |
Asset Growth % | - | -20.87% | -35.9% | 752.93% | 232.64% | -67.8% | -11.55% | -168.62% |
Total Current Liabilities | 75.76K | 68.67K | 1.64M | 3.92M | 17.19M | 18.29M | 9.14M | 3.07M |
Accounts Payable | 18.38K | 68.67K | 582.61K | 1.5M | 5.3M | 3.79M | 1.76M | 1.53M |
Days Payables Outstanding | 11.71K | 8.2K | 43.49K | 81.05K | 1.63K | 941.08 | 3.52K | 4.68K |
Short-Term Debt | 0 | 0 | 0 | 0 | 9.62M | 9.33M | 0 | 247.2K |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 234.26K | 1.15M | 490.22K | 230.04K | 7.05M | 1.02M |
Current Ratio | 79.98x | 66.94x | 1.88x | 6.69x | 0.34x | 0.05x | 0.66x | 1.41x |
Quick Ratio | 79.98x | 66.94x | 1.88x | 6.69x | 0.32x | 0.05x | 0.65x | 1.37x |
Cash Conversion Cycle | - | - | - | - | -583.26 | -911.23 | -3.08K | -4.26K |
Total Non-Current Liabilities | 6.86K | 9.64K | 0 | 0 | 68.92M | 280.88K | 24.36K | 18.31K |
Long-Term Debt | 0 | 0 | 0 | 0 | 118.86K | 0 | 24.36K | 18.31K |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 74.29K | 0 | 0 | 0 |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 3.07M | 0 | 0 | 0 |
Other Non-Current Liabilities | 6.86K | 9.64K | 0 | 0 | 65.66M | 280.88K | 0 | 0 |
Total Liabilities | 82.62K | 78.31K | 1.64M | 3.92M | 86.11M | 18.57M | 9.16M | 3.08M |
Total Debt | 0 | 0 | 0 | 0 | 9.89M | 9.45M | 48.77K | 289.92K |
Net Debt | -6.05M | -4.31M | -1.93M | -25.75M | 5.33M | 8.8M | -5.17M | -3.43M |
Debt / Equity | - | - | - | - | 7.04x | 0.98x | 0.00x | 0.02x |
Debt / EBITDA | - | - | - | - | - | - | - | -0.04x |
Net Debt / EBITDA | - | - | - | - | - | - | - | 0.51x |
Interest Coverage | - | - | - | - | -54.72x | -41.44x | -17.68x | -17.32x |
Total Equity | 6M▲ 0% | 4.73M▼ 21.1% | 1.45M▼ 69.4% | 22.39M▲ 1447.7% | 1.4M▼ 93.7% | 9.61M▲ 584.3% | 15.76M▲ 64.0% | 11.75M▲ 0% |
Equity Growth % | - | -21.08% | -69.44% | 1447.65% | -93.73% | 584.28% | 64.03% | 48.94% |
Book Value per Share | 527.49 | 416.28 | 127.21 | 1772.39 | 79.75 | 85.01 | 4.80 | 18.69 |
Total Shareholders' Equity | 6M | 4.73M | 1.45M | 22.39M | -5.6M | 9.61M | 15.76M | 11.75M |
Common Stock | 8 | 32 | 32 | 157 | 6 | 118 | 15 | 27 |
Retained Earnings | -939.87K | -2.54M | -5.96M | -19.38M | -56.79M | -115.68M | -131.21M | -135.43M |
Treasury Stock | 0 | 0 | 0 | -566.81K | -625.79K | -625.79K | -625.79K | -625.79K |
Accumulated OCI | -8 | 0 | 0 | 0 | 2.38M | -2.72M | -231.03K | -441.2K |
Minority Interest | 0 | 0 | 0 | 0 | 7.01M | 0 | 0 | 0 |
ONCO Cash Flow Statement
Onconetix, Inc. (ONCO) cash flow — operating, investing & free cash flow history
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Cash from Operations | -825.13K | -1.73M | -2.04M | -8.68M | -13.58M | -10.5M | -9.68M | -9.8M |
Operating CF Margin % | - | - | - | - | -23229.31% | -415.82% | -1186.99% | - |
Operating CF Growth % | - | -109.68% | -18.15% | -324.39% | -56.54% | 22.72% | 7.79% | -364.12% |
Net Income | -821.91K | -1.6M | -3.42M | -13.42M | -37.41M | -58.69M | -14.03M | -9.7M |
Depreciation & Amortization | 573 | 3.06K | 4.89K | 6.75K | 43.94K | 731.35K | 15.17K | 15.82K |
Stock-Based Compensation | 3.27K | 334.84K | 130.14K | 1.97M | 329.76K | 438.65K | 74.27K | 67.32K |
Deferred Taxes | 0 | -292.13K | 0 | 0 | -12.59K | -1.05M | 0 | 0 |
Other Non-Cash Items | 0 | 292.13K | 23.44K | 202.51K | 21.84M | 49.61M | 6.68M | 2.22M |
Working Capital Changes | -7.05K | -468.56K | 1.21M | 2.56M | 1.62M | -1.54M | -2.42M | -2.39M |
Change in Receivables | -8.33K | -1.48K | -114.96K | -23.33K | -62.29K | 116.68K | -318.69K | -7.4K |
Change in Inventory | 0 | 1.48K | 0 | 0 | -315.83K | -62.27K | -73.72K | 28.95K |
Change in Payables | 18.38K | 50.29K | 336.71K | 1.09M | 3.37M | -1.48M | -1.09M | -1.06M |
Cash from Investing | -4.5K | -11.79K | -1.92K | -32.66K | -8.65M | -28.47K | 0 | 0 |
Capital Expenditures | -4.5K | -11.79K | -1.92K | -9.34K | -55.04K | -28.47K | 0 | 0 |
CapEx % of Revenue | - | - | - | - | 94.15% | 1.13% | - | 0% |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | -23.33K | -8.59M | 0 | 0 | 0 |
Cash from Financing | 6.88M | 0 | -334.19K | 32.53M | 1.04M | 6.74M | 14.45M | 12.21M |
Debt Issued (Net) | -54.62K | 0 | 0 | 0 | -1M | 3.65M | -5.78M | -4.69M |
Equity Issued (Net) | 6.93M | 0 | -334.19K | 34.3M | 2.24M | 3.48M | 20.23M | 16.91M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | -206.4K | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | -566.81K | -58.98K | -718 | 0 | 6.39M |
Other Financing | 0 | 0 | -334.19K | -1.77M | -204.63K | -187.28K | -926 | -250 |
Net Change in Cash | 6.05M▲ 0% | -1.74M▼ 128.8% | -2.38M▼ 36.6% | 23.82M▲ 1100.9% | -21.2M▼ 189.0% | -3.91M▲ 81.6% | 4.57M▲ 217.1% | 2.14M▲ 0% |
Free Cash Flow | -829.63K▲ 0% | -1.74M▼ 110.0% | -2.05M▼ 17.5% | -8.68M▼ 324.4% | -13.64M▼ 57.0% | -10.52M▲ 22.8% | -9.68M▲ 8.0% | -9.8M▲ 0% |
FCF Margin % | - | - | - | - | -23323.46% | -416.95% | -1186.99% | -1333% |
FCF Growth % | - | -109.97% | -17.47% | -324.45% | -57.01% | 22.82% | 8.04% | -34.48% |
FCF per Share | -72.96 | -153.18 | -179.94 | -687.56 | -774.25 | -93.09 | -2.95 | -15.59 |
FCF Conversion (FCF/Net Income) | 1.00x | 1.08x | 0.60x | 0.65x | 0.36x | 0.18x | 0.69x | 1.01x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 379.41K | 0 | 163.38K |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ONCO Key Ratios
Onconetix, Inc. (ONCO) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -29.81% | -110.59% | -112.61% | -314.47% | -1065.65% | -110.6% | -105.46% |
Return on Invested Capital (ROIC) | -653.01% | - | - | -1603.32% | -336.95% | -32.81% | -56.54% |
Gross Margin | - | - | - | -1927.93% | 41.8% | 77.62% | 79.63% |
Net Margin | - | - | - | -63986.48% | -2325.21% | -1720.98% | -1319.55% |
Debt / Equity | - | - | - | 7.04x | 0.98x | 0.00x | 0.02x |
Interest Coverage | - | - | - | -54.72x | -41.44x | -17.68x | -17.32x |
FCF Conversion | 1.08x | 0.60x | 0.65x | 0.36x | 0.18x | 0.69x | 1.01x |
Revenue Growth | - | - | - | - | 4217.31% | -67.7% | -61.81% |
Related:ONCO Dividend History·ONCO Revenue History·ONCO Price History·ONCO P/E History·ONCO Financial Ratios·ONCO Institutional Holders
ONCO SEC Filings & Documents
Onconetix, Inc. (ONCO) SEC filings — annual & quarterly reports (10-K, 10-Q)
ONCO Frequently Asked Questions
Onconetix, Inc. (ONCO) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Onconetix, Inc. (ONCO) reported $0.7M in revenue for fiscal year 2025.
Onconetix, Inc. (ONCO) saw revenue decline by 67.7% over the past year.
Onconetix, Inc. (ONCO) reported a net loss of $9.7M for fiscal year 2025.
Dividend & Returns
Onconetix, Inc. (ONCO) has a return on equity (ROE) of -110.6%. Negative ROE indicates the company is unprofitable.
Onconetix, Inc. (ONCO) had negative free cash flow of $9.8M in fiscal year 2025, likely due to heavy capital investments.